针对PI3K/AKT/mTOR途径用于乳腺癌治疗的战略进展
Pankaj Garg1, Sravani Ramisetty2, Meera Nair3
1Department of Chemistry, GLA University, Mathura, Uttar Pradesh 281406, India.
Biochemical pharmacology
|March 6, 2025
概括
针对PI3K/AKT/mTOR通路对于晚期乳腺癌 (BC) 治疗至关重要. 本综述详细介绍了途径失调,当前的抑制剂和未来的策略,如免疫疗法,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 乳腺癌 (BC) 影响全球数百万人,需要先进的治疗策略.
- PI3K/AKT/mTOR途径是BC进展的组成部分,影响瘤生长,存活率和治疗耐药性.
- 这种途径的失调是BC发育和治疗挑战的重要因素.
研究的目的:
- 审查PI3K/AKT/mTOR途径在乳腺癌中的失调机制.
- 总结针对这种途径的当前治疗策略,包括抑制剂和组合疗法.
- 探索BC治疗的未来方向,重点关注下一代抑制剂,个性化药物和免疫疗法集成.
主要方法:
- 对乳腺癌中PI3K/AKT/mTOR通路研究的综合文献综述.
- 对导致途径失调的遗传变异 (例如,PIK3CA突变,PTEN损失) 的分析.
- 评估针对该途径的当前和新兴治疗干预措施.
主要成果:
- 由PIK3CA和PTEN损失等遗传突变驱动的PI3K/AKT/mTOR通路失调是乳腺癌的一个关键特征.
- 向抑制剂 (PI3K,AKT,mTOR) 和组合疗法在克服耐药性和提高治疗疗效方面表现有前途.
- 以生物标志物为指导的个性化治疗计划和免疫疗法整合代表着未来有希望的治疗途径.
结论:
- 准PI3K/AKT/mTOR通路为改善乳腺癌治疗结果提供了显著的潜力.
- 未来的研究应该专注于开发新的抑制剂,个性化方法和组合策略,包括免疫疗法.
- 对这种途径的更好理解和治疗向对于改善乳腺癌患者的生存率和生活质量至关重要.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
23.2K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
